23
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Effects of Val 5-Angiotensin II-Amide and of Hydrochlorothiazide on the Kidneys of Renal Hypertensive Rats

      research-article
      Nephron
      S. Karger AG

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Angiotensin II-amide administered intravenously at 0.2 µg/kg·min together with isotonic saline to rats with either DCA-induced or renal hypertension had the same diuretic and natriuretic effects as in normal rats. In renal hypertension (induced by a clip on one renal artery leaving the other kidney untouched) the normal overall diuretic response appeared to be due to the clamped kidney only. In the unclamped kidney of renal hypertensive rats the tubular diuretic and natriuretic response to angiotensin was abolished. Hydrochlorothiazide (5 mg/kg i.v., followed by 1 mg/kg •min) also failed to elicit its normal natriuretic response in the unclamped kidney. This failure, apparently, was the consequence of a greater depression of GFR (C<sub>In</sub>) in the unclamped kidney.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1965
          1965
          25 November 2008
          : 2
          : 2
          : 95-106
          Affiliations
          Department of Pharmacology, University of Lausanne, and Research Laboratories, Pharmaceutical Department, CIBA Limited, Basle
          Article
          179379 Nephron 1965;2:95–106
          10.1159/000179379
          4284015
          8640506a-79c2-48ad-9758-df67f2bad880
          © 1965 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 12
          Categories
          Paper

          Cardiovascular Medicine,Nephrology
          Cardiovascular Medicine, Nephrology

          Comments

          Comment on this article